Isolation of multi-resistant carbapenemase-producing Pseudomonas aeruginosa (VIM-2) and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (SHV-2) in a perianal ulcer in a patient with hematological disease [2];Aislamiento de Pseudomonas aeruginosa multirresistente productora de carbapenemasa (VIM-2) y de Klebsiella pneumoniae productora de betalactamasa de espectro extendido (SHV-2) en una úlcera perianal de un patiente hematológico

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 9, 2005, Pages 574-575

  Gutiérrez Urbón, Olivia ^a   Requena Rodríguez, Maria José ^b   Díaz Antolín, Paz ^b   Oliver Palomo, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; CORTICOSTEROID; ENZYME; FUSIDIC ACID; GENTAMICIN; IMIPENEM; MEROPENEM; PERMANGANATE POTASSIUM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULFADIAZINE; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC PROPHYLAXIS; ANUS DISEASE; ANUS ULCER; BACTERIUM ISOLATION; CASE REPORT; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME; ULCER;

EID: 28144435400     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13080272     Document Type: Article

References (11)

1. Bradford, PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
2. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002;8:321-31.
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Approved Standard M100-S14. Wayne: National Committee for Clinical Laboratory Standards (NCCLS);2004.
4. VIM,a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical strain. Antimicrob Agents Chemother. 1999;43:1584-90.
5. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000;44:891-97.
6. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, et al. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother. 1994;38:71-8.
7. IMP allelic variants carried by gene cassettes of different phytogeny. Antimicrob Agents Chemother. 2000;44:1229-35.
8. Coque TM, Oliver A, Pérez-Díaz JC, Baquero F, Cantón R. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid 1989 to 2000). Antimicrob Agents Chemother. 2002;46:500-10.
9. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634-40.
10. Prats G, Miró E, Mirelis B, Poirel L, Bellais S, Nordmann P. First isolation of a carbapenem-hydrolyzing β-lactamase in Pseudomonas aeruginosa in Spain. Antimicrob Agents Chemother. 2002;46:932-3.
11. Miró E, Navarro F, Gómez L, Pericas R, Sánchez F, Mirelis B, et al. Carbapenemasas en Pseudomonas aeruginosa: seguimiento epidemiológico desde 1996. XI Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Bilbao, 16-19 de mayo de 2004. Comunicación 444. p. 157.